H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Harmony Biosciences Holdings today and set a price target of $55.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Patrick Trucchio has given his Buy rating due to a combination of factors related to Harmony Biosciences Holdings’ promising developments in their epilepsy treatment pipeline. The recent preliminary data from the Phase 3 ARGUS trial for EPX-100 in Dravet syndrome showed a significant reduction in seizures, which is a positive indicator of the drug’s efficacy and safety. This data, which will be presented at the American Epilepsy Society meeting, strengthens the clinical validation of EPX-100 and suggests a favorable risk/benefit profile.
Additionally, the drug’s lack of interaction with other medications in a separate study further supports its potential as a cornerstone in Harmony’s strategy to expand into rare epilepsies. The promising results from the EPX-100 program, along with the anticipated pivotal data from trials in 2026, underpin Trucchio’s confidence in Harmony’s valuation. Despite inherent risks in clinical development and commercialization, the strong data and strategic growth opportunities justify the Buy rating and the $55 price target.
In another report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $46.00 price target.